Last reviewed · How we verify
SA4503 Low
At a glance
| Generic name | SA4503 Low |
|---|---|
| Sponsor | M's Science Corporation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Preliminary Efficacy Study of SA4503 in Subjects Recovering From Ischemic Stroke (PHASE2)
- SA4503 8-Week Study in Major Depressive Disorder (MDD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SA4503 Low CI brief — competitive landscape report
- SA4503 Low updates RSS · CI watch RSS
- M's Science Corporation portfolio CI